A method for determining the activity of creatininase includes providing an amount of creatininase to be measured for enzyme activity and providing an excess amount of creatinine, the excess amount being greater than an amount that will ordinarily react with the amount of creatininase. The method further includes reacting the amount of creatininase with the excess amount of creatinine to produce creatine. The method further includes reacting the creatine with diacetyl and 1-naphatol and producing a pink color. The method further includes measuring an intensity of the pink color and determining an amount of the creatine that was created based on the intensity. The method further includes calculating a specific activity of the creatininase based on the amount of creatine.

Methods and compositions for risk detection, early diagnosis, prognosis, and monitoring of sleepiness in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with sleepiness, or an earlier sample from the individual of interest.

Methods and compositions for risk detection, early diagnosis, prognosis, and monitoring of sleepiness in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with sleepiness, or an earlier sample from the individual of interest.

Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.

The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

The biometric system comprises: a measurement cartridge; and a meter, equipped with the measurement cartridge, for measuring an analyte present in a sample of the measurement cartridge. The measurement cartridge comprises a reagent container, a capillary module, and a reagent rod. The reagent container receives a liquid reagent and has a top sealed with a sealing film. The capillary module comprises a capillary tube which is located on an upper side of the reagent container and collects the sample by a capillary phenomenon, and the capillary tube is introduced into the reagent container by rupturing a contact portion to the sealing film by an applied pressure.

The biometric system comprises: a measurement cartridge; and a meter, equipped with the measurement cartridge, for measuring an analyte present in a sample of the measurement cartridge. The measurement cartridge comprises a reagent container, a capillary module, and a reagent rod. The reagent container receives a liquid reagent and has a top sealed with a sealing film. The capillary module comprises a capillary tube which is located on an upper side of the reagent container and collects the sample by a capillary phenomenon, and the capillary tube is introduced into the reagent container by rupturing a contact portion to the sealing film by an applied pressure.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.